Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Dementia01:30

Dementia

108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
108
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

111
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
111
  1. Home
  3. Research Domains
  5. Psychology
  7. Applied And Developmental Psychology
  9. Testing, Assessment And Psychometrics
  11. "real-world" Eligibility For Anti-amyloid Treatment In A Tertiary Memory Clinic Setting.
  1. Home
  3. Research Domains
  5. Psychology
  7. Applied And Developmental Psychology
  9. Testing, Assessment And Psychometrics
  11. "real-world" Eligibility For Anti-amyloid Treatment In A Tertiary Memory Clinic Setting.

Related Experiment Video

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.2K

"Real-world" eligibility for anti-amyloid treatment in a tertiary memory clinic setting.

Sinthujah Vigneswaran1,2,3, Everard G B Vijverberg2, Frederik Barkhof4

  • 1Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|June 12, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Eligibility for anti-amyloid treatment (AAT) in Alzheimer's disease (AD) is limited in real-world memory clinics. Only 6% of new patients met strict criteria, highlighting challenges for AAT accessibility.

Keywords:
Alzheimer's diseaseanti‐amyloid treatmenteligibilityreal‐world evidence

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

118
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.9K

Related Experiment Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.2K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

118
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.9K

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Societal impact of anti-amyloid treatment (AAT) for Alzheimer's disease (AD) hinges on patient eligibility.
  • Current estimates suggest 1-18% of AD patients may qualify, but real-world data are scarce.
  • This study evaluated AAT eligibility in a tertiary memory clinic setting.

Purpose of the Study:

  • To assess the real-world eligibility of patients for anti-amyloid treatment (AAT) at a tertiary memory clinic.
  • To determine the proportion of patients meeting criteria for AAT based on approved guidelines.

Main Methods:

  • 1309 new patients at Alzheimer Center Amsterdam (2020-2022) underwent standardized diagnostic workup.
  • Eligibility for AAT was determined using lecanemab's approved label guidelines.
  • Exclusion criteria included amyloid status, microbleed count, apolipoprotein E ε4/ε4 homozygosity, and anticoagulant use.

    • Main Results:

    • Of 1309 patients, 514 (39%) had clinical mild cognitive impairment (MCI) or AD.
    • Initially, 108 patients (8% of all, 21% of MCI/AD) met core criteria.
    • After exclusions, 79 patients (6% of all, 15% of MCI/AD) were eligible for AAT.

    Conclusions:

    • Real-world eligibility for AAT in tertiary memory clinics is limited.
    • Current guidelines result in a low percentage of eligible patients for AAT.
    • Findings underscore challenges in the broad clinical application of AAT for Alzheimer's disease.